Natixis Acquires Shares of 48,400 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Natixis bought a new position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 48,400 shares of the biotechnology company's stock, valued at approximately $608,000. Natixis owned about 0.05% of Rocket Pharmaceuticals at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in RCKT. Wellington Management Group LLP lifted its holdings in Rocket Pharmaceuticals by 24.5% in the fourth quarter. Wellington Management Group LLP now owns 13,995,177 shares of the biotechnology company's stock valued at $175,919,000 after acquiring an additional 2,753,033 shares during the period. Vanguard Group Inc. increased its position in shares of Rocket Pharmaceuticals by 18.8% during the 4th quarter. Vanguard Group Inc. now owns 6,577,595 shares of the biotechnology company's stock valued at $82,680,000 after purchasing an additional 1,040,655 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Rocket Pharmaceuticals by 8.4% in the 4th quarter. Geode Capital Management LLC now owns 1,752,975 shares of the biotechnology company's stock worth $22,041,000 after purchasing an additional 135,109 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Rocket Pharmaceuticals by 15.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 656,090 shares of the biotechnology company's stock worth $8,247,000 after buying an additional 86,276 shares during the last quarter. Finally, Marshall Wace LLP grew its position in Rocket Pharmaceuticals by 4,422.4% during the fourth quarter. Marshall Wace LLP now owns 456,762 shares of the biotechnology company's stock valued at $5,741,000 after buying an additional 446,662 shares during the period. Institutional investors own 98.39% of the company's stock.

Insider Buying and Selling

In other news, insider Kinnari Patel purchased 21,099 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $4.70 per share, with a total value of $99,165.30. Following the purchase, the insider now owns 26,774 shares in the company, valued at approximately $125,837.80. This trade represents a 371.79 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Gaurav Shah purchased 20,000 shares of the business's stock in a transaction that occurred on Thursday, April 10th. The shares were purchased at an average price of $5.08 per share, for a total transaction of $101,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 792,680 shares in the company, valued at $4,026,814.40. The trade was a 2.59 % increase in their position. The disclosure for this purchase can be found here. 28.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Chardan Capital decreased their price target on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Wedbush assumed coverage on Rocket Pharmaceuticals in a report on Monday, December 30th. They issued an "outperform" rating and a $32.00 target price on the stock. BMO Capital Markets initiated coverage on Rocket Pharmaceuticals in a research report on Wednesday, March 12th. They set an "outperform" rating and a $50.00 target price on the stock. The Goldman Sachs Group reduced their price target on Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Finally, Scotiabank increased their price objective on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, Rocket Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $43.00.

Rocket Pharmaceuticals Price Performance

Shares of NASDAQ RCKT traded up $0.11 during midday trading on Tuesday, reaching $7.27. 373,404 shares of the stock traded hands, compared to its average volume of 1,327,376. The company's 50 day moving average is $7.57 and its 200 day moving average is $11.25. Rocket Pharmaceuticals, Inc. has a one year low of $4.55 and a one year high of $26.98. The stock has a market capitalization of $774.67 million, a PE ratio of -2.64 and a beta of 1.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.06. On average, equities research analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current year.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.